Zynaxis news

The Malvern, Penn., company reduced its staff by 25 percent - to 59 from 78 - which it said will save an estimated $3 million annually. The company has $7.9 million in cash. Prior to the cuts, ZNXS was burning $900,000 per month.

ZNXS will continue to develop oligonucleotides coupled to its Zyn-Linker delivery system, which it said has shown improved intracellular delivery in preliminary experiments. The company will also continue its anti-cancer program, which has demonstrated in animal models that anti-cancer agents coupled to Zyn-Linkers show improved efficacy and reduced toxicity. ...